MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-26-2026
22nd Century Group DSO Ratio 2011-2026 | XXII
Annual DSO Ratio 22nd Century Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 54.9 | 25.2 | 75.3 | 35.7 | 73.6 | 28 | 12.2 | 12 | 21 | 1.22 | 2.19 | 31.8 | 2.48 | 788 | 8.37 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 788 | 1.22 | 78.2 |
Quarterly DSO Ratio 22nd Century Group
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74.3 | 87.8 | 46.1 | - | 32.5 | 24.1 | 24.1 | - | 88.3 | 101 | 75.5 | - | 22.6 | 18.5 | 9.1 | - | 19.4 | 22.7 | 28 | 27 | 26.9 | 30.6 | 19.6 | 10.9 | 12.2 | 13.6 | 12.6 | 11.1 | 12.7 | 11.5 | 13.6 | 14.7 | 19.3 | 22.4 | 20.4 | 1.12 | 1.21 | 1.32 | 1.39 | 1.59 | 1.75 | 2.03 | 3.79 | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.4 | 44.2 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 101 | 1.12 | 25.2 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
2.94 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Exelixis
EXEL
|
43.4 | $ 46.1 | -5.34 % | $ 12.5 B | USA |
 |
Fortress Biotech
FBIO
|
115 | $ 2.42 | -4.96 % | $ 67.5 M | USA |
 |
Heron Therapeutics
HRTX
|
198 | $ 1.23 | -6.11 % | $ 205 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
20.5 | $ 75.89 | -1.26 % | $ 12.1 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
77.8 | $ 211.16 | -9.2 % | $ 3.86 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.45 | 4.49 % | $ 3.72 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
70.6 | $ 101.38 | -7.9 % | $ 5.09 B | USA |
 |
MannKind Corporation
MNKD
|
26.2 | $ 3.64 | 2.11 % | $ 1.11 B | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.15 | - | $ 655 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.6 | 7.46 % | $ 5.93 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 20.92 | -13.47 % | $ 2.66 B | USA |
 |
Genmab A/S
GMAB
|
97.9 | $ 27.08 | -2.9 % | $ 16.7 B |  Danmark |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Aravive
ARAV
|
16.8 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |